• Company
• Leclza’s partner ‘Rybrevant’ lands in Big 5 hospitals
• by Eo, Yun-Ho Feb 17, 2023 05:50am

• Opinion
• [Reporter's view] An uncomfortable gift from the gov
• by Kim, Jin-Gu Feb 17, 2023 05:50am

• Policy
• NHIS President “will improve the PVA system"
• by Lee, Tak-Sun Feb 17, 2023 05:49am

• Company
• Samsung Bioepis Soliris patent partially invalidated
• by Kim, Jin-Gu Feb 16, 2023 05:52am

• Product
• Australian supply of Tylenol 500 mg is embarrassing
• by Kang, Hye-kyung Feb 16, 2023 05:52am

• Company
• Open Innovation Trend
• by Jung, Sae-Im Feb 16, 2023 05:52am

• Opinion
• [Reporter's view]National Security & the Price Policy
• by Lee, Jeong-Hwan Feb 16, 2023 05:52am

• Company
• Sorrento Theraputics Inc. filed for bankruptcy protection
• by Hwang, Jin-joon Feb 16, 2023 05:51am

• Company
• Exports of Dong-A ST’s anemia biosimilar exceed KRW 10 bil
• by Chon, Seung-Hyun Feb 16, 2023 05:51am

• Policy
• Rebamipide eye drops will be reimb next month
• by Lee, Tak-Sun Feb 16, 2023 05:51am